Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – Here’s What Happened

Shares of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week low on Wednesday . The company traded as low as $71.83 and last traded at $72.48, with a volume of 2727219 shares traded. The stock had previously closed at $73.85.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share-repurchase authorization to $5 billion, a direct capital-return move that can support the stock by reducing float and boosting EPS. Boston Scientific Raises Share Buyback Authorization To $5B
• Positive Sentiment: Analysts at TD Cowen and Bank of America reiterated Buy ratings and maintained price targets, framing recent share-price weakness as an opportunity given growth and margin prospects. TD Cowen Buy Rating Coverage Bank of America Buy Rating Coverage
• Positive Sentiment: Unusually large call-option volume (noted by market watchers) signals bullish positioning from some traders, which can amplify near-term upside and volatility. (Trading report)
• Neutral Sentiment: Market-commentary pieces highlight Boston Scientific as a long-term thematic play (aging population) and argue for large upside over many years — these are bullish in tone but speculative and long-horizon. 3 Reasons BSX Could 5X (Motley Fool)
• Neutral Sentiment: Market summaries and headlines noted BSX outperformed the broader market session, reflecting the combined effect of company news and analyst commentary. Zacks Market Recap
• Negative Sentiment: Multiple law firms have filed or announced investigations into Boston Scientific (class-action notices and potential securities-fraud claims), creating legal and reputational risk that could pressure the stock if litigation proceeds or leads to material settlements. Robbins LLP Class Action Notice Levi & Korsinsky Complaint Notice Portnoy Law Firm Investigation

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. Citigroup decreased their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. reduced their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Finally, National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The business’s 50-day moving average is $85.52 and its 200-day moving average is $94.83. The company has a market capitalization of $108.22 billion, a PE ratio of 37.59, a PEG ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently modified their holdings of the stock. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter worth about $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp grew its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Finally, Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.